ONWARD: FY24 Update – Commercial inflection begins, near-term milestones ahead
This morning, ONWARD shared FY 2024 business update highlighting a highly comprehensive list of achievements across clinical development, IP and corporate actions, while posting the first commercial sales of ARC EX following its de Novo FDA approval on 20th December. As communicated previously, two
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.